Entest BioMedical, Inc. (Entest) is a development-stage company. During the fiscal year ended August 31, 2012, the Company�s business consists of the development and commercialization of immunotherapeutic therapies for the veterinary market, as well as the acquisition and operation of veterinary hospitals. The Company is focusing its research and development efforts toward the development and commercialization of the ImenVax family of canine cancer vaccines. ImenVax I is a therapeutic for canine cancer, which involves isolating tumor cells from the patient and then placing the cells into a cell implant device that is inserted subcutaneously into the patient. ImenVax II, which utilizes cell lines for sustained release of immunologically relevant cytokines for maximum anti-tumor immune responses.